Tag Archives: celltrion healthcare

October, 2018

11 October
Celltrion and Teva Announce FDA Advisory Committee Recommends Approval of CT-P10, a Proposed Rituximab Biosimilar

SILVER SPRING, Md. & JERUSALEM–(BUSINESS WIRE)– Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan®1 (rituximab) for the treatment of …
Share

13 June
Celltrion Showcases Promising Preliminary Results for New Subcutaneous Formulation of CT-P13 in Rheumatoid Arthritis

AMSTERDAM–(BUSINESS WIRE)–New data presented at the Annual European Congress of Rheumatology (EULAR 2018) show that the subcutaneous (SC) formulation of CT-P13 is comparable in terms of efficacy and safety with the intravenous (IV) formulation of CT-P13 for the treatment of patients with rheumatoid arthritis (RA) up to week 30. The …
Share

14 November
Celltrion Presents New Data Supporting Efficacy and Safety of its Biosimilars

WASHINGTON–(BUSINESS WIRE)–New data presented today at the 2016 American College of Rheumatology (ACR) Annual Meeting demonstrate that the efficacy and safety profile of CT-P10 (biosimilar rituximab) in rheumatoid arthritis (RA) patients is comparable to patients treated with originator rituximab over 24 weeks.1,2 A total of 372 RA patients (161 patients …
Share

18 March
Studies Show Comparable Efficacy and Safety after Switching from Remsima from Originator

AMSTERDAM–(BUSINESS WIRE)–Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to biosimilar infliximab from originator infliximab.1-10 These studies, presented at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO), further support the appropriate switching of patients …
Share

25 February
Celltrion and Hospira Launch Biosimilars of Remicade in Major European Markets

Partners Hospira, Inc. and Celltrion Healthcare have launched a biosimilar version of Johnson & Johnson’s autoimmune drug Remicade across major European markets. Together, the companies are launching their biosimilar products in twelve European markets, including Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. …
Share